PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

ATTLAS Quality of Life: Four-Drug Regimen Shows No Detectable Global Decline

atezolizumabbevacizumabcarboplatinpaclitaxelpemetrexedcisplatinimmune checkpoint inhibitorEGFRALKnon-small-cell lung cancerpost-TKIquality of lifepatient-reported outcomesEORTC QLQ-C30QLQ-LC13peripheral neuropathyphase 3secondary analysis Oncology

Background Information

Assessing QoL in lung cancer: Atezolizumab plus bevacizumab shines despite chemo challenges.

Quality of life (QoL) is crucial in assessing treatment impact for patients with advanced lung cancer, especially post-tyrosine kinase inhibitor therapy. ABCP regimen showed early QoL impairment that stabilized by week 24; no significant difference in overall QoL compared to PC was observed. The study highlights the importance of managing chemotherapy-related toxicities to maintain QoL while achieving symptom control in EGFR/ALK-mutated non-small-cell lung cancer. ABCP and PC regimens show similar QoL outcomes with distinct toxicity profiles, requiring careful patient management.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Kang EJ, Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ

Citation: Kang EJ, Park S, Kim TM, et al. Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK-Mutated Non-Small-Cell Lung Cancer. Cancer medicine. 2026;15(11). doi:10.1002/cam4.72405

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.